Recruiting studies: Lu 177 Psma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Functio
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT07169825 Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Canc
Phase 1 · 2 location(s) · Weill Medical College of Cornell University · NCT04886986 Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Phase 3 · 88 location(s) · Novartis Pharmaceuticals · NCT06855277 Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Phase 4 · 2 location(s) · Brigham and Women's Hospital · NCT06099093 Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate
Phase 1 · 1 location(s) · VitsGen Therapeutics Inc. · NCT07660211 Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Can
Phase 1 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT05398302 Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06145633 Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Pro
Phase 2 · 3 location(s) · University of Washington · NCT06526299 Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Adva
Phase 3 · 102 location(s) · Alliance for Clinical Trials in Oncology · NCT07200830 Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Phase 1/Phase 2 · 1 location(s) · Vadim S Koshkin · NCT05113537 Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
Phase 1 · 1 location(s) · Jean-Mathieu Beauregard · NCT06943495 A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI i
Phase 1/Phase 2 · 21 location(s) · Novartis Pharmaceuticals · NCT07226986 Neoadjuvant PSMA-RLT in Oligometastatic PCa
Phase 2 · 1 location(s) · Medical University of Vienna · NCT06259123 LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Ra
Phase N/A · 1 location(s) · Jules Bordet Institute · NCT07370597 ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients
Phase N/A · 1 location(s) · Hospital of Macerata · NCT06200558 Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resist
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06216249 A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in
Phase 1 · 21 location(s) · Novartis Pharmaceuticals · NCT06531499 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
NA · 1 location(s) · Peking Union Medical College Hospital · NCT05613738 Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Phase 1/Phase 2 · 21 location(s) · Blue Earth Therapeutics Ltd · NCT05413850 Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
Phase 2 · 4 location(s) · VA Office of Research and Development · NCT06084338 Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177
Phase N/A · 1 location(s) · Hannah Schaefer · NCT06720532 Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Phase 2 · 1 location(s) · Ebrahim S Delpassand · NCT06972628 Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer
Phase 2 · 16 location(s) · Hospices Civils de Lyon · NCT06866938 Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA
NA · 1 location(s) · Centre Henri Becquerel · NCT06450548 A Study of 177Lu-PSMA-617 in People With Gliomas
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07223034 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Phase 4 · 1 location(s) · VA Greater Los Angeles Healthcare System · NCT06706921 Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate
Phase N/A · 1 location(s) · University Hospital, Grenoble · NCT06828263 SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Phase N/A · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07096999 PSMA-RLT in Biochemically Recurrent PCa
Phase 2 · 1 location(s) · Medical University of Vienna · NCT06220188 A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer
Phase 1 · 3 location(s) · Jinming Zhang · NCT07096128

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.